Key clinical point:
Major finding: On average, warfarin patients had 8.8 concurrent active prescription drugs.
Study details: A review of medical records from 1,122 warfarin patients.
Disclosures: Dr. Jacobson reported having no financial disclosures.
Source: Jacobson A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018. Poster 2.
Jacobson A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018. Poster 2
This Week's Must Reads
Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7
CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P
Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.
New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460
JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.
Must Reads in Thrombosis
Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.
Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.
Sepsis-related coagulopathy and in-hospital death risk, Lyons PG et al. Crit Care Med. 2018 May;46(5):73642.
New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.